A total of 844 potentially useful individual articles were identified, but only 28 studies were eligible for inclusion. These studies examined a wide range of different pharmacological antiemetics, using different doses and comparators, and reported a variety of outcomes.
The majority of quantitative data reported the complete control of acute vomiting. Nausea outcomes were reported in only 10 studies.
For only two groups of studies was a pooled analysis possible. The use of additive steroids combined with 5-HT3 antagonists had been examined in two studies 3, 4 which are pooled and demonstrate good benefit. The other compared granisitron 20 microg/kg with 40 microg/kg and this demonstrated no clear difference in the doses 5, 6, 7 .
Discussion
This systematic review has demonstrated the existence of a surprisingly small number of trials addressing the prevention and treatment of chemotherapy induced nausea and vomiting in children.
While a clearly defined route, schedule or dose of maximal efficiency of any antiemetic medication cannot be determined from this review, there has been evidence to suggest benefit from the use of 5HT3 antagonists with dexamethasone, in highly emetogenic chemotherapy.
Future research questions should evaluate patient centred differences between the 5HT3 antagonists, explore dosing and duration and clarify the role of new agents. This research should be reported with validated age-appropriate measures and should be performed in conjunction with children, young people and families that have undergone chemotherapy 8 .
Introduction
Nausea and vomiting has continued to be a problem for children undergoing treatment for malignancies 1 
